pr1 leukemia peptide vaccine
Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)vaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
315 Active assets in the Myelodysplastic Syndrome (MDS) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sawa Ito, MD | Phase 4 | BB |
Anti-Thymoglobulin, Rabbit Peking University First Hospital | Phase 2/3 | BB |
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University | Phase 4 | BB |
FILGRASTIM City of Hope Medical Center | Phase 4 | BB |
Daunorubicin OHSU Knight Cancer Institute | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →